Loading...
Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?
With proteasome inhibitors (PIs) becoming clinically available since 2003, outcomes for patients with multiple myeloma (MM) have dramatically changed, improving quality of life and survival. Despite the impressive treatment success, however, almost all MM patients who initially respond to these PIs...
Na minha lista:
| Udgivet i: | Cancer Drug Resist |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
OAE Publishing Inc.
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8297691/ https://ncbi.nlm.nih.gov/pubmed/34308274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20517/cdr.2021.27 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|